UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 172

Sortiert nach

VEGF Receptor Signaling in Tumor Angiogenesis

The oncologist (Dayton, Ohio), 2000-04, Vol.5 (S1), p.3-10

McMahon, Gerald

2000

Link zum Volltext

Verfügbarkeit prüfen

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

PloS one, 2017-07, Vol.12 (7), p.e0181356-e0181356

2017

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis

The Journal of experimental medicine, 2005-03, Vol.201 (6), p.925-935

2005

Link zum Volltext

Verfügbarkeit prüfen

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments

Cancer biology & therapy, 2010-05, Vol.9 (10), p.764-777

2010

Link zum Volltext

Verfügbarkeit prüfen

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models

Cancer biology & therapy, 2010-05, Vol.9 (10), p.778-790

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies

Clinical cancer research, 2003-07, Vol.9 (7), p.2755-2768

2003

Link zum Volltext

Verfügbarkeit prüfen

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Blood, 2002-10, Vol.100 (8), p.2941-2949

2002

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

Journal of medicinal chemistry, 1999-12, Vol.42 (25), p.5120-5130

1999

Link zum Volltext

Verfügbarkeit prüfen

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

The FASEB journal, 2001-05, Vol.15 (7), p.1239-1241

2001

Link zum Volltext

Verfügbarkeit prüfen

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion

Molecular cancer therapeutics, 2003-11, Vol.2 (11), p.1085-1092

2003

Link zum Volltext

Verfügbarkeit prüfen

Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (∗)

The Journal of biological chemistry, 1995-10, Vol.270 (41), p.23975-23983

1995

Link zum Volltext

Verfügbarkeit prüfen

SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization

Oncogene, 2004-01, Vol.23 (4), p.873-882

2004

Link zum Volltext

Verfügbarkeit prüfen

FGF10 is an inducer and Pax6 a competence factor for lacrimal gland development

Development (Cambridge), 2000-06, Vol.127 (12), p.2563-2572

2000

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

Blood, 2002-07, Vol.100 (2), p.585-593

2002

Link zum Volltext

Verfügbarkeit prüfen

Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells

Toxicology letters, 2005-01, Vol.155 (1), p.41-50

2005

Link zum Volltext

Verfügbarkeit prüfen

Tyrphostins. 5. Potent Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinase: Structure−Activity Relationships in Quinoxalines, Quinolines, and Indole Tyrphostins

Journal of medicinal chemistry, 1996-05, Vol.39 (11), p.2170-2177

1996

Link zum Volltext

Verfügbarkeit prüfen

Structure-Based design and discovery of novel inhibitors of protein tyrosine phosphatases

Bioorganic & medicinal chemistry, 2003-04, Vol.11 (8), p.1835-1849

2003

Link zum Volltext

Verfügbarkeit prüfen

Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors

Cancer research (Chicago, Ill.), 2016-10, Vol.76 (19), p.5788-5797

2016

Link zum Volltext

Verfügbarkeit prüfen

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells

Clinical cancer research, 2017-05, Vol.23 (10), p.2565-2574

2017

Link zum Volltext

Verfügbarkeit prüfen

A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability

The Journal of pharmacology and experimental therapeutics, 2003-09, Vol.306 (3), p.838

2003

Link zum Volltext

Verfügbarkeit prüfen

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Nature cell biology, 2000-10, Vol.2 (10), p.737-744

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3835: An anti-MET IgG2 monoclonal antibody degrades both wild-type and exon 14 mutant MET receptor tyrosine kinase through a novel exon 14-independent mechanism and inhibits tumor growth

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3835-3835

2016

Link zum Volltext

Verfügbarkeit prüfen

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

Cancer chemotherapy and pharmacology, 2011-06, Vol.67 (6), p.1389-1400

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1696: Blocking activity of a novel anti-MET humanized monoclonal antibody, KTN0216, is enhanced by IgG2 isotype in HGF-dependent and Met-amplified tumors

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.1696-1696

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 172

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(151)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(171)
Japanisch
(24)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(108)
Life Sciences & Biomedicine
(98)
Humans
(78)
Animals
(56)
Biological And Medical Sciences
(54)
Medical Sciences
(44)
Mice
(39)
Oncology
(31)
Indoles - Pharmacology
(30)
Enzyme Inhibitors - Pharmacology
(28)
Male
(28)
Pharmacology. Drug Treatments
(28)
Antineoplastic Agents
(26)
Female
(26)
Pyrroles - Pharmacology
(23)
Receptor Protein-Tyrosine Kinases - Antagonists & Inhibitors
(22)
Cell Biology
(16)
Receptors, Vascular Endothelial Growth Factor
(16)
Chemotherapy
(15)
Middle Aged
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

VEGF Receptor Signaling in Tumor Angiogenesis

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis

PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments

Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models

Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases

Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival

Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion

Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (∗)

SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization

FGF10 is an inducer and Pax6 a competence factor for lacrimal gland development

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors

Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells

Tyrphostins. 5. Potent Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinase: Structure−Activity Relationships in Quinoxalines, Quinolines, and Indole Tyrphostins

Structure-Based design and discovery of novel inhibitors of protein tyrosine phosphatases

Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells

A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

Abstract 3835: An anti-MET IgG2 monoclonal antibody degrades both wild-type and exon 14 mutant MET receptor tyrosine kinase through a novel exon 14-independent mechanism and inhibits tumor growth

Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship

Abstract 1696: Blocking activity of a novel anti-MET humanized monoclonal antibody, KTN0216, is enhanced by IgG2 isotype in HGF-dependent and Met-amplified tumors

Suchergebnisse filtern